No Result
View All Result
  • Login
Friday, August 7, 2026
theadvisertimes.com
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
No Result
View All Result
theadvisertimes.com
No Result
View All Result
Home Money

The 10 Common Drugs That Just Got Significantly Cheaper Under New Medicare Rules

by theadvisertimes.com
5 months ago
in Money
Reading Time: 4 mins read
A A
0
The 10 Common Drugs That Just Got Significantly Cheaper Under New Medicare Rules
Share on FacebookShare on TwitterShare on LInkedIn


Image Source: Shutterstock

If you’ve felt the sting of rising prescription costs, this may be the first real relief in years. Thanks to new federal rules under the Inflation Reduction Act, Medicare can now negotiate prices on some of the most expensive medications in the country. For 2026, that means 10 widely used drugs are seeing major price cuts—some as high as nearly 80%. These savings are expected to impact millions of seniors and could dramatically lower out-of-pocket costs. Here’s what you need to know about these Medicare drug savings—and how they might benefit you.

Eliquis, Xarelto, and Blood Thinner Costs Are Finally Dropping

Blood thinners like Eliquis and Xarelto have long been among the most expensive medications for seniors. These drugs are essential for preventing strokes and dangerous blood clots, making them non-negotiable for many patients. Under the new Medicare drug savings rules, both medications are now included in the first round of negotiated prices. That means lower monthly costs for millions of people who rely on them daily. For many seniors, this change alone could save hundreds—or even thousands—each year.

Diabetes Medications Are Seeing Major Price Relief

Diabetes treatment is one of the biggest cost burdens for Medicare recipients. Drugs like Jardiance, Januvia, Farxiga, and NovoLog insulin are now part of the negotiated list. These medications help control blood sugar and prevent serious complications, but their prices have steadily climbed over the years. Now, Medicare drug savings are bringing those costs down significantly. This is especially important as diabetes rates continue to rise among older adults.

Heart Failure Drug Entresto Is Becoming More Affordable

Entresto is a life-saving medication for people with heart failure, but its price has been a major barrier. It’s now included in the list of drugs with newly negotiated prices. That means patients who depend on it may finally see meaningful financial relief. Lower costs could also improve medication adherence, which leads to better health outcomes. This is a win for both patients and the healthcare system overall.

Arthritis and Autoimmune Treatments Are Included Too

Drugs like Enbrel and Stelara treat conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. These are chronic conditions that require ongoing treatment, often at a very high cost. Both medications are part of the Medicare drug savings program. For patients managing long-term conditions, this could significantly reduce annual expenses. It also makes advanced treatments more accessible to those who previously struggled to afford them.

Cancer Treatment Costs Are Getting Some Relief

Cancer medications are often among the most expensive prescriptions on the market. Imbruvica, used to treat certain blood cancers, is now included in the negotiated pricing program. This is a major step toward reducing financial toxicity for cancer patients. Lower drug costs can ease the burden on both patients and their families. It also highlights how Medicare drug savings are targeting some of the most critical treatments.

How Much You Could Actually Save

The negotiated prices range from about 38% to 79% off previous list prices. That’s a dramatic reduction compared to typical annual price increases. In total, Medicare is expected to save around $6 billion in 2026 alone. Patients themselves could save an additional $1.5 billion in out-of-pocket costs. These numbers show just how significant Medicare drug savings could be for everyday Americans.

When These Lower Prices Take Effect

The new negotiated prices officially went into effect in 2026. That means Medicare Part D plans are already adjusting to reflect these lower costs. If you’re enrolled in Medicare, you may start seeing savings immediately, depending on your plan. It’s important to review your coverage to understand how much you’ll benefit. Timing matters, especially if you’re considering switching plans.

What You Should Do Right Now to Maximize Savings

If you’re on Medicare, now is the time to take action. Here is what you should be doing…

Review your current prescriptions and see if any are on the negotiated list.
Talk to your doctor about switching to covered alternatives if possible.
Compare Part D plans during open enrollment to find the best deal.

For years, high drug prices have been one of the biggest financial pressures facing seniors. The new Medicare drug savings program marks a major shift in how prescription costs are managed. While it doesn’t solve every problem, it’s a meaningful step toward affordability. Millions of Americans are already seeing relief, and more changes are on the way. If you rely on prescription medications, this could be one of the most important financial developments of the decade.

Have you noticed any savings on your prescriptions yet, or are you still paying high costs?

What to Read Next

The New “TrumpRx” Portal: How to Access GLP-1 Weight Loss Drugs for $50

7 Prescription Drugs That Often See Price Changes Each Spring — What to Watch For

New Study: Popular Weight-Loss Drugs Linked to 30% Spike in ‘Silent’ Health Risk

5 of the Cheapest Prescription Drugs in America — and How Patients Are Still Overpaying for Them

8 Over-the-Counter Drugs the FDA Just Flagged as Dangerous for Anyone Over 60



Source link

Tags: cheaperCommondrugsMedicarerulessignificantly
ShareTweetShare
Previous Post

Mortgage Rates May Keep Rising Even as Fed Holds Steady

Next Post

US couple buys Tel Aviv seafront apartment for NIS 17.3m

Related Posts

Stock news for investors: Quarterly earnings from Telus, Shopify, BCE, and more

Stock news for investors: Quarterly earnings from Telus, Shopify, BCE, and more

by theadvisertimes.com
August 6, 2026
0

The company reported a loss attributable to common shareholders of $1.8 billion or $1.17 per share for the quarter ended...

7 Warning Signs an Older Adult May Be Under Financial Pressure

7 Warning Signs an Older Adult May Be Under Financial Pressure

by theadvisertimes.com
August 6, 2026
0

It often starts with what seems like a harmless favor. A relative offers to help pay bills online. A new...

When Should You Claim Social Security? 7 Factors That Matter More Than Age

When Should You Claim Social Security? 7 Factors That Matter More Than Age

by theadvisertimes.com
August 6, 2026
0

Choosing when to claim Social Security feels like a once-in-a-lifetime decision, and that’s because it is. Claim too early and...

7 Homeowners Insurance Questions Every Retiree Should Ask Before the Next Big Storm

7 Homeowners Insurance Questions Every Retiree Should Ask Before the Next Big Storm

by theadvisertimes.com
August 6, 2026
0

After a major storm, many homeowners discover an expensive truth: having homeowners insurance doesn’t necessarily mean every type of damage...

5 Ways to Turn Downtime, Debt and Discounts Into Real Money

5 Ways to Turn Downtime, Debt and Discounts Into Real Money

by theadvisertimes.com
August 6, 2026
0

Cash-back apps, discount memberships and reward programs are easy to wave off as gimmicks or clutter on your phone. Used...

6-Figure Trade Jobs. Surely Not? Nvidia CEO Says ‘The Skilled Craft Segment of Every Economy Is Going to See a Boom’

6-Figure Trade Jobs. Surely Not? Nvidia CEO Says ‘The Skilled Craft Segment of Every Economy Is Going to See a Boom’

by theadvisertimes.com
August 6, 2026
0

In January 2026, Nvidia CEO Jensen Huang stood on a stage in Davos and told a room full of the...

Next Post
US couple buys Tel Aviv seafront apartment for NIS 17.3m

US couple buys Tel Aviv seafront apartment for NIS 17.3m

Views for next Fed rate cut pushed back after hot inflation report

Views for next Fed rate cut pushed back after hot inflation report

  • Trending
  • Comments
  • Latest
SEC pushes private market access, but retail is already in

SEC pushes private market access, but retail is already in

July 16, 2026
How I Maximize My Sapphire Reserve Dining Credit

How I Maximize My Sapphire Reserve Dining Credit

July 10, 2026
The Weekly Notable Startup Funding Report: 6/22/26 – AlleyWatch

The Weekly Notable Startup Funding Report: 6/22/26 – AlleyWatch

June 21, 2026
The 10 Largest NYC Tech Startup Funding Rounds of June 2026 – AlleyWatch

The 10 Largest NYC Tech Startup Funding Rounds of June 2026 – AlleyWatch

July 6, 2026
The Weekly Notable Startup Funding Report: 7/20/26 – AlleyWatch

The Weekly Notable Startup Funding Report: 7/20/26 – AlleyWatch

July 20, 2026
The Hidden Cost of Chaos: Challenges with Spreadsheet-Based Channel Management in 2026

The Hidden Cost of Chaos: Challenges with Spreadsheet-Based Channel Management in 2026

May 6, 2026
Playtika dips after warning of second-half weakness

Playtika dips after warning of second-half weakness

0
Doximity shares double. Here’s what’s driving it 

Doximity shares double. Here’s what’s driving it 

0
Stock news for investors: Quarterly earnings from Telus, Shopify, BCE, and more

Stock news for investors: Quarterly earnings from Telus, Shopify, BCE, and more

0
Malachyte Raises M to Solve E-Commerce’s Biggest Blind Spot: the Visitor Who Never Logs In – AlleyWatch

Malachyte Raises $10M to Solve E-Commerce’s Biggest Blind Spot: the Visitor Who Never Logs In – AlleyWatch

0
Stock Market: Two AI Names Bounce From Chip Sell-Off; Three More Stocks On Watch

Stock Market: Two AI Names Bounce From Chip Sell-Off; Three More Stocks On Watch

0
The Declaration and Dinesh D’Souza’s “Revisionist History”

The Declaration and Dinesh D’Souza’s “Revisionist History”

0
Doximity shares double. Here’s what’s driving it 

Doximity shares double. Here’s what’s driving it 

August 7, 2026
Stock Market: Two AI Names Bounce From Chip Sell-Off; Three More Stocks On Watch

Stock Market: Two AI Names Bounce From Chip Sell-Off; Three More Stocks On Watch

August 7, 2026
Spokane Fires Burned a Path of Devastation. Experts Say Get Used to It

Spokane Fires Burned a Path of Devastation. Experts Say Get Used to It

August 7, 2026
Malachyte Raises M to Solve E-Commerce’s Biggest Blind Spot: the Visitor Who Never Logs In – AlleyWatch

Malachyte Raises $10M to Solve E-Commerce’s Biggest Blind Spot: the Visitor Who Never Logs In – AlleyWatch

August 7, 2026
WonderFi’s founder says Canada’s business climate forced him to sell to Robinhood

WonderFi’s founder says Canada’s business climate forced him to sell to Robinhood

August 7, 2026
Bitcoin collateral: MARA’s 0M Long Ridge financing

Bitcoin collateral: MARA’s $600M Long Ridge financing

August 7, 2026
theadvisertimes.com

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Economy
  • Financial Planning
  • Investing
  • Market Analysis
  • Markets
  • Money
  • Personal Finance
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Doximity shares double. Here’s what’s driving it 
  • Stock Market: Two AI Names Bounce From Chip Sell-Off; Three More Stocks On Watch
  • Spokane Fires Burned a Path of Devastation. Experts Say Get Used to It
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • About Us
  • Contact Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.